1. Home
  2. STE vs GMAB Comparison

STE vs GMAB Comparison

Compare STE & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo STERIS plc (Ireland)

STE

STERIS plc (Ireland)

HOLD

Current Price

$218.36

Market Cap

22.3B

Sector

Health Care

ML Signal

HOLD

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$24.97

Market Cap

19.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STE
GMAB
Founded
1985
1999
Country
United States
Denmark
Employees
3700
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.3B
19.1B
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
STE
GMAB
Price
$218.36
$24.97
Analyst Decision
Buy
Strong Buy
Analyst Count
6
7
Target Price
$275.20
$40.93
AVG Volume (30 Days)
804.8K
1.4M
Earning Date
02-04-2026
05-07-2026
Dividend Yield
1.16%
N/A
EPS Growth
62.73
N/A
EPS
5.69
N/A
Revenue
$5,459,515,000.00
N/A
Revenue This Year
$9.88
$17.80
Revenue Next Year
$6.32
$14.86
P/E Ratio
$38.33
$1.90
Revenue Growth
6.24
N/A
52 Week Low
$204.90
$17.24
52 Week High
$269.44
$35.43

Technical Indicators

Market Signals
Indicator
STE
GMAB
Relative Strength Index (RSI) 34.62 27.07
Support Level $209.98 $20.83
Resistance Level $254.67 $33.75
Average True Range (ATR) 5.68 0.62
MACD -0.80 -0.11
Stochastic Oscillator 27.18 5.15

Price Performance

Historical Comparison
STE
GMAB

About STE STERIS plc (Ireland)

Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: